Florida Cancer Specialists P.L. Revenue and Competitors
Estimated Revenue & Valuation
- Florida Cancer Specialists P.L.'s estimated annual revenue is currently $873.9M per year.
- Florida Cancer Specialists P.L.'s estimated revenue per employee is $378,000
Employee Data
- Florida Cancer Specialists P.L. has 2312 Employees.
- Florida Cancer Specialists P.L. grew their employee count by 15% last year.
Florida Cancer Specialists P.L. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.2M | 22 | -21% | N/A | N/A |
#2 | $7.3M | 34 | -13% | N/A | N/A |
#3 | $7.3M | 34 | 55% | N/A | N/A |
#4 | $16.5M | 68 | 3% | N/A | N/A |
#5 | $17.5M | 72 | 60% | N/A | N/A |
#6 | $15.3M | 63 | 15% | N/A | N/A |
#7 | $6.9M | 32 | -30% | N/A | N/A |
#8 | $0.3M | 2 | 100% | N/A | N/A |
#9 | $50.2M | 169 | 7% | N/A | N/A |
#10 | $10.2M | 47 | 38% | N/A | N/A |
What Is Florida Cancer Specialists P.L.?
Now celebrating its 30th anniversary, Florida Cancer Specialists & Research Institute (FCS) is the largest independent medical oncology/hema-tology practice in the United States. With over 170 physicians, 110 nurse practitioners and physician assistants and over 80 locations in our network, we are committed to providing world-class cancer care in community-based settings close to home. Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, FCS offers patients access to more clinical trials than any private oncology practice in Florida.
keywords:N/AN/A
Total Funding
2312
Number of Employees
$873.9M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Florida Cancer Specialists P.L. News
Authors from the Community Oncology Alliance and Avalere Health present ... Gordan, of Florida Cancer Specialists and Research Institute,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $300M | 2410 | 10% | $560.5M |
#2 | $634M | 2516 | N/A | N/A |
#3 | $442.3M | 3159 | 4% | N/A |
#4 | $1385M | 3664 | 11% | N/A |
#5 | $300M | 3814 | 16% | N/A |